Oligonucleotides are exploding as a therapeutic modality. The ability of oligonucleotide therapies to modulate disease mechanisms at the mRNA level opens up the potential to treat pathologies previously considered “undruggable”.
The molecular properties of oligonucleotides place them somewhere between small molecules and protein therapeutics. SCIEX recognizes the special analytical challenges that oligonucleotide therapeutics present to scientists. We have partnered with scientists in the pharmaceutical and biopharmaceutical industries to develop precise, sensitive and efficient analytical solutions to enable your IND or NDA seeking programs.
Our market-leading negative-ion performance across our mass spectrometry portfolio delivers extreme sensitivity for your most challenging therapeutic oligonucleotides. You will not only see a boost in sensitivity with microflow chromatography, but also a decrease in system contamination and downtime for cleaning. Confidently run your analyses with the ease of connecting SCIEX sources and employing instrumentation designed specifically for microflow.
Excellent negative ion mode performance ensures high sensitivity for the lowest levels of oligonucleotide qualification.
Great negative ion mode performance with the ability to simultaneously quantify both analytes and metabolites.
Experience the intelligent union of high sensitivity, ease of use and robustness to quantify oligonucleotides.
Compliant-ready solution optimized for qualitative and quantitative data analysis.
This webinar presents an overview of the most sophisticated tools for both oligonucleotide qualification and characterization.
Presented by: Sean McCarthy PhD, Global Technical Marketing Manager, SCIEX
Oligonucleotide Analysis Better Sensitivity. Greater Robustness. Faster Turn-Around Times.
Extending the Lower Limits of Quantification of a Therapeutic Oligonucleotide Through Microflow LC-MS/MS
Oligonucleotides using High Resolution MS/MS on the TripleTOF® 5600 System